Table 1.
Characteristics of Subjects
| Variable | All Subjects (n = 85) | Subjects Without Hyperkalemia (n = 79) | Subjects With Hyperkalemia (n = 6) |
|---|---|---|---|
| Age at spironolactone start, mean (SD), y | 16.6 (1.7) | 16.7 (1.7) | 16.0 (1.4) |
| Female gender identity, n (%) | 82 (96) | 76 (96) | 6 (100) |
| Nonbinary gender identity, n (%) | 3 (4) | 3 (4) | 0 (0) |
| Race | |||
| White, n (%) | 59 (69) | 54 (68) | 5 (83) |
| Black or African American, n (%) | 2 (2) | 2 (3) | 0 (0) |
| Asian, n (%) | 2 (2) | 2 (3) | 0 (0) |
| Other, n (%) | 8 (9) | 8 (10) | 0 (0) |
| Unknown, n (%) | 14 (16) | 13 (16) | 1 (17) |
| Hispanic or Latino, n (%) | 5 (6) | 5 (6) | 0 (0) |
| Using GnRH analog, n (%) | 19 (22) | 18 (23) | 1 (17) |
| Using estrogen, n (%) | 73 (86) | 68 (86) | 5 (83) |
| Number of potassium measurements per subject, median (range) | 3 (1–10) | 3 (1–10) | 4.5 (1–8) |
| Baseline potassium measurement available, n (%) | 70 (82) | 65 (82) | 5 (83) |
| Serum potassium, mean (SD), mmol/L | 4.25 (0.4) | 4.20 (0.3) | 4.65 (0.5) |
| Spironolactone dose, mean (SD), mg/d | 105 (42) | 105 (42) | 108 (49) |